1. Search Result
Search Result
Results for "

GPR109A

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Recombinant Proteins

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107579

    AY 25712

    GPR109A Cardiovascular Disease
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin .
    Acifran
  • HY-119222
    GSK256073
    1 Publications Verification

    GPR109A Metabolic Disease
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073
  • HY-10680
    MK-6892
    4 Publications Verification

    GPR109A Cancer
    MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. Ki and GTPγS EC50 of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.
    MK-6892
  • HY-107581

    GPR109A Metabolic Disease
    MK-1903 is a potent and selective hydroxycarboxylic acid receptor 2 (HCA2, GPR109A) full agonist .
    MK-1903
  • HY-W095200

    GPR109A Cardiovascular Disease
    GPR109 receptor agonist-2 (Compound 5) is a selective GPR109a agonist with a pEC50 of 5.53 .
    <em>GPR109</em> receptor agonist-2
  • HY-103252
    Monomethyl fumarate
    3 Publications Verification

    GPR109A Drug Metabolite Neurological Disease Inflammation/Immunology
    Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease .
    Monomethyl fumarate
  • HY-13008
    MK-0354
    1 Publications Verification

    GPR109A Cardiovascular Disease
    MK-0354 is a partial agonist of GPR109a receptor, for hGPR109a/ mGPR109a with EC50 of 1.65/1.08 μM, showed no activation of GPR109b.
    MK-0354
  • HY-103252S1

    Isotope-Labeled Compounds GPR109A Drug Metabolite Neurological Disease Inflammation/Immunology
    Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].
    Monomethyl fumarate-d5
  • HY-111143

    nAChR Metabolic Disease
    SCH-900271 is an orally active, potent nicotinic acid receptor (NAR) agonist with an EC50 of 2 nM in the hu-GPR109a assay. SCH-900271 exhibits dose-dependent inhibition of plasma free fatty acid (FFA). SCH-900271 has an improved therapeutic window to flushing .
    SCH-900271
  • HY-135982
    GPR81 agonist 1
    1 Publications Verification

    GPR109A Metabolic Disease
    GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50s of 58 nM and 50 nM for human and mouse GPR81, respectively. GPR81 agonist 1 inhibits lipolysis in differentiated 3T3-L1 adipocytes. GPR81 agonist 1 suppresses lipolysis in mice without cutaneous flushing. GPR81 agonist 1 displays remarkable selectivity for GPR81 over GPR109a .
    GPR81 agonist 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: